NeoGenomics (NEO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.07
- Estimate
- $0.06
- Surprise
- +26.2%
- Revenue (period 2026-09-30)
- $209.3M
- Score today
- 6.3/10
Revenue source: xbrl.
How the report landed
NeoGenomics (NEO) beat the $0.06 estimate with adjusted EPS of $0.07 — a large 26.2% upside surprise.
Coverage in the report window
- BTIG Reiterates Buy on NeoGenomics, Maintains $28 Price Target — benzinga, 2026-10-29
- NeoGenomics Reports Third Quarter 2026 Results — fiscal.ai, 2026-10-28
- NeoGenomics Q3 2026 Earnings Call Transcript — benzinga, 2026-10-28
Where TrendMatrix's rating stands now
TrendMatrix currently rates NEO Sell at 6.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +26.2% surprise compares with a +231.4% four-quarter average.
What argues against it
- Quality below floor (3.7 < 4.0)
- Reward/Risk 0.4:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $17.99
- Price target
- $19.01
- Stop
- $16.73
- Upside to target
- +5.7%
- Reward-to-risk
- 0.4:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
NEO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $2.34B
- P/E (fwd)
- 52.5
- 52-week range
- $7.07–$20.15
- Off 52-week high
- 10.7%
- RSI (14)
- 69
- Volume vs avg
- 1.20×
- Score today
- 6.3/10